ADIL
insider transactionsADIAL PHARMACEUTICALS, INC. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
+36.4K
36.4K buy · 0 sell
Net value · 90d
$100.0K
$100.0K in · $0 out
Sentiment · 90d
Net buying
100% buying · 0% selling
Open-market trades · 90d
1
36.4K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Chief Development Officer
$0
232.4K sh
Own New
-
Grant·A
Chief Development Officer
$0
232.4K sh
Own +357%
-
Buy·P
Director
$100.0K
36.4K sh · $2.75
Own New
-
Grant·A
Chief Development Officer
—
101 sh
Own +6%
-
Grant·A
Chief Development Officer
—
1.8K sh
Own New
-
Grant·A
Chief Development Officer
—
3.4K sh
Own New
-
Grant·A
Chief Development Officer
—
61.6K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Chief Operating Officer
$0
26.5K sh
Own +203923%
-
Grant·A
Vinay Shah KEY
Chief Financial Officer
$0
17.3K sh
Own New
-
Grant·A
Director
$0
9.2K sh
Own +32804%
-
Grant·A
Director
$0
9.2K sh
Own New
-
Grant·A
Cary J Claiborne KEY
Chief Executive Officer
$0
38.0K sh
Own +1562%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 12, 2026 | Matt Davidson | Grant A | 232.4K | $0 |
| Jun 12, 2026 | Matt Davidson | Grant A | 232.4K | $0 |
| Jun 12, 2026 | Wendy B. Young | Buy P | 36.4K | $100.0K |
| Jun 11, 2026 | Matt Davidson | Grant A | 101 | — |
| Jun 11, 2026 | Matt Davidson | Grant A | 1.8K | — |
| Jun 11, 2026 | Matt Davidson | Grant A | 3.4K | — |
| Jun 11, 2026 | Matt Davidson | Grant A | 61.6K | — |
| Apr 7, 2026 | Kermit J. Anderson | Grant A | 9.2K | $0 |
| Apr 7, 2026 | Tony Goodman | Grant A | 26.5K | $0 |
| Apr 7, 2026 | Vinay Shah KEY | Grant A | 17.3K | $0 |
| Apr 7, 2026 | Kevin Schuyler | Grant A | 9.2K | $0 |
| Apr 7, 2026 | Robertson H. Gilliland | Grant A | 9.2K | $0 |
| Apr 7, 2026 | Cary J Claiborne KEY | Grant A | 38.0K | $0 |
About ADIL insider trading
This page tracks insider transactions for ADIAL PHARMACEUTICALS, INC. (ADIL) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.